Cargando…

GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment

Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Y, Huang, H, Li, J, Zhang, J, Gao, J, Lu, B, Huang, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674369/
https://www.ncbi.nlm.nih.gov/pubmed/23681232
http://dx.doi.org/10.1038/cddis.2013.162
_version_ 1782272363079925760
author Yu, Y
Huang, H
Li, J
Zhang, J
Gao, J
Lu, B
Huang, C
author_facet Yu, Y
Huang, H
Li, J
Zhang, J
Gao, J
Lu, B
Huang, C
author_sort Yu, Y
collection PubMed
description Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found that p53 protein expression was upregulated in GADD45β−/− cells upon arsenite exposure as compared with those in GADD45β+/+ cells. Further studies showed that GADD45β attenuated p53 protein expression through Src/protein phosphatase 2A/murine double minute 2-dependent p53 protein-degradation pathway. Moreover, we identified that GADD45β-mediated p53 protein degradation was crucial for its anti-apoptotic effect due to arsenite exposure, whereas increased JNK activation was not involved in the increased cell apoptotic response in GADD45β−/− cells under same experimental conditions. Collectively, our results demonstrate a novel molecular mechanism responsible for GADD45β protection of arsenite-exposed cells from cell death, which provides insight into our understanding of GADD45β function and a unique compound arsenite as both a cancer therapeutic reagent and an environmental carcinogen. Those novel findings may also enable us to design more effective strategies for utilization of arsenite for the treatment of cancers.
format Online
Article
Text
id pubmed-3674369
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36743692013-06-06 GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment Yu, Y Huang, H Li, J Zhang, J Gao, J Lu, B Huang, C Cell Death Dis Original Article Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found that p53 protein expression was upregulated in GADD45β−/− cells upon arsenite exposure as compared with those in GADD45β+/+ cells. Further studies showed that GADD45β attenuated p53 protein expression through Src/protein phosphatase 2A/murine double minute 2-dependent p53 protein-degradation pathway. Moreover, we identified that GADD45β-mediated p53 protein degradation was crucial for its anti-apoptotic effect due to arsenite exposure, whereas increased JNK activation was not involved in the increased cell apoptotic response in GADD45β−/− cells under same experimental conditions. Collectively, our results demonstrate a novel molecular mechanism responsible for GADD45β protection of arsenite-exposed cells from cell death, which provides insight into our understanding of GADD45β function and a unique compound arsenite as both a cancer therapeutic reagent and an environmental carcinogen. Those novel findings may also enable us to design more effective strategies for utilization of arsenite for the treatment of cancers. Nature Publishing Group 2013-05 2013-05-16 /pmc/articles/PMC3674369/ /pubmed/23681232 http://dx.doi.org/10.1038/cddis.2013.162 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Yu, Y
Huang, H
Li, J
Zhang, J
Gao, J
Lu, B
Huang, C
GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title_full GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title_fullStr GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title_full_unstemmed GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title_short GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
title_sort gadd45β mediates p53 protein degradation via src/pp2a/mdm2 pathway upon arsenite treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674369/
https://www.ncbi.nlm.nih.gov/pubmed/23681232
http://dx.doi.org/10.1038/cddis.2013.162
work_keys_str_mv AT yuy gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT huangh gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT lij gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT zhangj gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT gaoj gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT lub gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment
AT huangc gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment